we refer to these assets as our micro rna product platform . we are using our micro rna product platform to develop chemically modified , single-stranded oligonucleotides that we call anti-mirs to modulate micro rnas and return diseased cells to their healthy state . we believe micro rnas may be transformative in the field of drug discovery and that anti-mirs may become a new and major class of drugs with broad therapeutic application , much like small molecules , biologics and monoclonal antibodies . in addition to our micro rna product platform , we have established regulus micro markers sm , a division focused on identifying micro rnas as biomarkers of human disease to support our therapeutic pipeline , collaborators and strategic partners . regulus micro markers sm utilizes a clinically-validated , highly reproducible technology platform to identify micro rnas as potential biomarkers for disease and we control key intellectual property and know-how related to the division . we believe that micro rna biomarkers may be used to select optimal patient segments in clinical trials and to monitor disease progression or relapse . we believe these micro rna biomarkers can be applied toward drugs that we develop and drugs developed by other companies with which we partner or collaborate . we have completed a research collaboration with biogen focused on the discovery of micro rnas as biomarkers for multiple sclerosis and have also completed research for another leading , commercial-stage pharmaceutical company to explore micro rnas as biomarkers for specific patient populations . we also maintain several academic research collaborations focused on the identification of micro rnas as biomarkers in multiple disease areas . ‘ clinical map initiative ' goals to advance our micro rna therapeutics pipeline and biomarkers platform over the next several years , we have outlined specific goals under our ‘ clinical map initiative ' strategy . we are developing rg-101 , a galnac-conjugated anti-mir targeting mir-122 , a host factor for the hepatitis c virus , or hcv , infection . in addition , we are developing rg-012 , an anti-mir targeting micro rna-21 for the treatment of alport syndrome , a life-threatening kidney disease driven by genetic mutations with no approved therapy . we are also advancing several programs toward clinical development in areas such as oncology and fibrosis , both independently and with our strategic alliance partners astrazeneca and sanofi . under our strategic alliance with astrazeneca , astrazeneca recently commenced clinical development of rg-125 , a galnac-conjugated anti-mir targeting micro rna-103/107 for the treatment of nonalcoholic steatohepatitis , or nash , in patients with type 2 diabetes/pre-diabetes . rg-101 : in august 2015 , we initiated a phase ii study investigating rg-101 designed to evaluate a shortened , four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of rg-101 at day 1 and day 29 , in combination with oral direct-acting antiviral agents harvoni® , olysio® , and daklinza® for 28 days . in february , 2016 , we announced interim results from the clinical study . thirty-eight patients had been evaluated through 8 weeks of follow up . ninety-seven percent of those patients ( 37/38 ) had hcv rna viral load measurements below the limit of quantification . for those patients through 12 weeks of follow-up , 100 % remained below the limit of quantification ( 14/14 ) . to date , rg-101 has been generally well 49 tolerated with the majority of adverse events considered mild or moderate ( headache and fatigue most commonly reported , each at approximately 11 % ) , two saes reported during the follow-up period , and with no study discontinuations . the primary endpoint analysis ( 12 week follow up ) for all 79 patients in the study are anticipated to be reported in second quarter of 2016. to expand the potential development of rg-101 , in november 2015 we entered into a clinical trial collaboration and formulation agreement with gsk llc . in the first quarter of 2016 , we plan to initiate a phase ii study evaluating the potential to achieve sustained viral responses post treatment with a single subcutaneous administration of rg-101 in combination with daily oral administrations of gsk2878175 , a non-nucleoside ns5b polymerase inhibitor , for up to 12 weeks in treatment-naïve patients chronically infected with hcv genotypes 1 and 3. concurrently , gsk will work on developing a long-acting parenteral formulation for injection ( “ lap ” ) of gsk2878175 which could improve patient compliance through reduced dosing intervals and potentially extend opportunities for hcv therapeutic intervention . this lap formulation of gsk2878175 may be used in potential additional clinical trials together with rg-101 following completion of the planned phase ii study . neither we nor gsk has any further obligations or commitments beyond the contemplated study under the clinical trial collaboration agreement . rg-012 : in june 2015 , we initiated a phase i study to evaluate the safety , tolerability and pharmacokinetics of subcutaneous dosing of rg-012 in healthy volunteers and the study is now complete . forty healthy volunteer subjects were enrolled in this first-in-human , single ascending dose study . rg-012 was well-tolerated and there were no serious adverse events reported . we also continue to enroll alport syndrome patients in our global athena natural history of disease study , which is designed to characterize the natural decline of renal function ( as measured by established renal markers ) in alport syndrome patients over time . we believe the data from the athena study will provide the clinical basis for the design of a phase ii proof-of-concept study to monitor the therapeutic effect of rg-012 on the decline in renal function in patients with alport syndrome . we plan to initiate a phase ii proof-of-concept study evaluating the efficacy of rg-012 in alport syndrome patients during 2016. rg-125 : astrazeneca initiated a phase i study evaluating rg-125 in humans in december 2015 , earning regulus a $ 10.0 million milestone from the collaboration . story_separator_special_tag in august 2014 , we and biogen entered into a new collaboration and license agreement to collaborate on micro rna biomarkers for ms. revenue recognized from our agreement with biogen increased to $ 1.8 million for the year ended december 31 , 2015 compared to $ 1.1 million for the year ended december 31 , 2014 . this increase was primarily a result of amortization of the $ 2.0 million upfront payment received in august 2014 which was recognized over the estimated period of performance , ending in september 2015. in january 2015 , may 2015 and september 2015 , we earned research milestone payments under the august 2014 collaboration and license agreement of $ 0.1 million , $ 0.3 million , and $ 0.3 million , respectively . revenue recognized from our product development and commercialization agreement with gsk decreased to zero for the year ended december 31 , 2015 compared to $ 3.5 million for the year ended december 31 , 2014 . in october 2014 , we received written notice from gsk of its election to terminate the product development and commercialization agreement . the effective date of the termination was january 15 , 2015. as of december 31 , 2015 , we had $ 3.3 million of deferred revenue , which consisted of payments received through our strategic alliances that have not yet been recognized in accordance with our revenue recognition policies . research and development expenses research and development expenses were $ 56.4 million for the year ended december 31 , 2015 , compared to $ 41.0 million for the year ended december 31 , 2014 . this change was primarily driven by a net increase in our aggregate pre-clinical studies and clinical trial program costs of $ 8.3 million for the year ended december 31 , 2015 , compared to the year ended december 31 , 2014 . specifically , clinical trial costs for rg-101 increased by $ 6.4 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . this increase was due to costs incurred associated with the phase ii study for rg-101 . pre-clinical study costs for rg-125 increased by $ 4.3 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . this increase was due to costs incurred associated with additional research and development activities and product manufacturing to support the initiation of a phase i clinical study . this increase was partially offset by a decrease in clinical trial costs for rg-012 of $ 2.4 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . 54 research and development personnel costs , including stock based compensation , increased by $ 5.1 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . this was principally driven by an increase in non-cash stock-based compensation expense of $ 4.1 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . in june 2015 , we incurred a non-recurring severance charge of $ 1.3 million associated with the resignation of our former chief scientific officer , including $ 0.9 million of non-cash stock-based compensation expense . we expect our research and development expenses to increase for the foreseeable future as we continue to conduct our ongoing clinical studies , initiate additional clinical studies and advance our pre-clinical research programs toward the clinic , including other ind-enabling activities . general and administrative expenses general and administrative expenses were $ 19.1 million for the year ended december 31 , 2015 compared to $ 11.5 million for the year ended december 31 , 2014 . this change was primarily driven by an increase in personnel costs , including non-cash stock based compensation , of $ 5.6 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . in june 2015 , we incurred a non-recurring severance charge of $ 3.3 million associated with the resignation of our former chief executive officer , including $ 2.3 million of non-cash stock-based compensation expense . in december 2015 , we incurred a non-recurring severance charge of $ 1.0 million associated with the resignation of our former chief business officer , including $ 0.7 million of non-cash stock-based compensation expense . in addition , changes in general and administrative expenses were due to increases in external service costs and other operating expenses associated with general business activities of $ 2.0 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . gain/loss from valuation of convertible note payable we recorded a loss from changes in value of the convertible note payable of $ 1.8 million for the year ended december 31 , 2015 compared to a loss of $ 12.1 million for the year ended december 31 , 2014 . changes in value were driven by changes in our stock price during the respective periods . in january 2015 , the convertible note payable was converted into 1,356,738 shares of our common stock at a conversion price of $ 4.00 per share . comparison of the years ended december 31 , 2014 and 2013 the following table summarizes the results of our operations for the periods indicated ( in thousands ) : replace_table_token_5_th revenue under strategic alliances and collaborations the following table summarizes our total revenues for the periods indicated ( in thousands ) : replace_table_token_6_th 55 revenue under strategic alliances and collaborations was $ 7.7 million for the year ended december 31 , 2014 compared to $ 19.6 million for the year ended december 31 , 2013. revenue recognized from our strategic alliance with sanofi decreased to $ 1.0 million for the year ended december 31 , 2014 , compared to $ 15.3 million in 2013. revenue recognized under the

liquidity and capital resources since our inception through december 31 , 2015 , we have received $ 75.1 million principally from upfront payments , research funding and preclinical milestones from our strategic alliances and collaborations , $ 257.1 million from the sale of our equity and convertible debt securities , including $ 70.0 million in net proceeds from our initial public offering and concurrent private placement of our common stock in october 2012 , $ 45.8 million in net proceeds from our public offering in july 2013 , and $ 76.3 million in net proceeds from our public offering in november 2014 . 56 as of december 31 , 2015 , we had $ 115.3 million in cash , cash equivalents and short-term investments , including $ 1.3 million in restricted cash . the following table shows a summary of our cash flows for the years ended december 31 , 2015 and 2014 ( in thousands ) : replace_table_token_7_th operating activities net cash used in operating activities increased to $ 49.9 million for the year ended december 31 , 2015 , compared to $ 39.5 million and $ 28.3 million for the years ended december 31 , 2014 and december 31 , 2013 , respectively . increases in cash used in operating activities have been attributable , in part , to net losses of $ 55.7 million , $ 56.7 million and $ 18.7 million for the years ended december 31 , 2015 , 2014 and 2013 , respectively .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources since our inception through december 31 , 2015 , we have received $ 75.1 million principally from upfront payments , research funding and preclinical milestones from our strategic alliances and collaborations , $ 257.1 million from the sale of our equity and convertible debt securities , including $ 70.0 million in net proceeds from our initial public offering and concurrent private placement of our common stock in october 2012 , $ 45.8 million in net proceeds from our public offering in july 2013 , and $ 76.3 million in net proceeds from our public offering in november 2014 . 56 as of december 31 , 2015 , we had $ 115.3 million in cash , cash equivalents and short-term investments , including $ 1.3 million in restricted cash . the following table shows a summary of our cash flows for the years ended december 31 , 2015 and 2014 ( in thousands ) : replace_table_token_7_th operating activities net cash used in operating activities increased to $ 49.9 million for the year ended december 31 , 2015 , compared to $ 39.5 million and $ 28.3 million for the years ended december 31 , 2014 and december 31 , 2013 , respectively . increases in cash used in operating activities have been attributable , in part , to net losses of $ 55.7 million , $ 56.7 million and $ 18.7 million for the years ended december 31 , 2015 , 2014 and 2013 , respectively .
```    
 Suspicious Activity Report : we refer to these assets as our micro rna product platform . we are using our micro rna product platform to develop chemically modified , single-stranded oligonucleotides that we call anti-mirs to modulate micro rnas and return diseased cells to their healthy state . we believe micro rnas may be transformative in the field of drug discovery and that anti-mirs may become a new and major class of drugs with broad therapeutic application , much like small molecules , biologics and monoclonal antibodies . in addition to our micro rna product platform , we have established regulus micro markers sm , a division focused on identifying micro rnas as biomarkers of human disease to support our therapeutic pipeline , collaborators and strategic partners . regulus micro markers sm utilizes a clinically-validated , highly reproducible technology platform to identify micro rnas as potential biomarkers for disease and we control key intellectual property and know-how related to the division . we believe that micro rna biomarkers may be used to select optimal patient segments in clinical trials and to monitor disease progression or relapse . we believe these micro rna biomarkers can be applied toward drugs that we develop and drugs developed by other companies with which we partner or collaborate . we have completed a research collaboration with biogen focused on the discovery of micro rnas as biomarkers for multiple sclerosis and have also completed research for another leading , commercial-stage pharmaceutical company to explore micro rnas as biomarkers for specific patient populations . we also maintain several academic research collaborations focused on the identification of micro rnas as biomarkers in multiple disease areas . ‘ clinical map initiative ' goals to advance our micro rna therapeutics pipeline and biomarkers platform over the next several years , we have outlined specific goals under our ‘ clinical map initiative ' strategy . we are developing rg-101 , a galnac-conjugated anti-mir targeting mir-122 , a host factor for the hepatitis c virus , or hcv , infection . in addition , we are developing rg-012 , an anti-mir targeting micro rna-21 for the treatment of alport syndrome , a life-threatening kidney disease driven by genetic mutations with no approved therapy . we are also advancing several programs toward clinical development in areas such as oncology and fibrosis , both independently and with our strategic alliance partners astrazeneca and sanofi . under our strategic alliance with astrazeneca , astrazeneca recently commenced clinical development of rg-125 , a galnac-conjugated anti-mir targeting micro rna-103/107 for the treatment of nonalcoholic steatohepatitis , or nash , in patients with type 2 diabetes/pre-diabetes . rg-101 : in august 2015 , we initiated a phase ii study investigating rg-101 designed to evaluate a shortened , four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of rg-101 at day 1 and day 29 , in combination with oral direct-acting antiviral agents harvoni® , olysio® , and daklinza® for 28 days . in february , 2016 , we announced interim results from the clinical study . thirty-eight patients had been evaluated through 8 weeks of follow up . ninety-seven percent of those patients ( 37/38 ) had hcv rna viral load measurements below the limit of quantification . for those patients through 12 weeks of follow-up , 100 % remained below the limit of quantification ( 14/14 ) . to date , rg-101 has been generally well 49 tolerated with the majority of adverse events considered mild or moderate ( headache and fatigue most commonly reported , each at approximately 11 % ) , two saes reported during the follow-up period , and with no study discontinuations . the primary endpoint analysis ( 12 week follow up ) for all 79 patients in the study are anticipated to be reported in second quarter of 2016. to expand the potential development of rg-101 , in november 2015 we entered into a clinical trial collaboration and formulation agreement with gsk llc . in the first quarter of 2016 , we plan to initiate a phase ii study evaluating the potential to achieve sustained viral responses post treatment with a single subcutaneous administration of rg-101 in combination with daily oral administrations of gsk2878175 , a non-nucleoside ns5b polymerase inhibitor , for up to 12 weeks in treatment-naïve patients chronically infected with hcv genotypes 1 and 3. concurrently , gsk will work on developing a long-acting parenteral formulation for injection ( “ lap ” ) of gsk2878175 which could improve patient compliance through reduced dosing intervals and potentially extend opportunities for hcv therapeutic intervention . this lap formulation of gsk2878175 may be used in potential additional clinical trials together with rg-101 following completion of the planned phase ii study . neither we nor gsk has any further obligations or commitments beyond the contemplated study under the clinical trial collaboration agreement . rg-012 : in june 2015 , we initiated a phase i study to evaluate the safety , tolerability and pharmacokinetics of subcutaneous dosing of rg-012 in healthy volunteers and the study is now complete . forty healthy volunteer subjects were enrolled in this first-in-human , single ascending dose study . rg-012 was well-tolerated and there were no serious adverse events reported . we also continue to enroll alport syndrome patients in our global athena natural history of disease study , which is designed to characterize the natural decline of renal function ( as measured by established renal markers ) in alport syndrome patients over time . we believe the data from the athena study will provide the clinical basis for the design of a phase ii proof-of-concept study to monitor the therapeutic effect of rg-012 on the decline in renal function in patients with alport syndrome . we plan to initiate a phase ii proof-of-concept study evaluating the efficacy of rg-012 in alport syndrome patients during 2016. rg-125 : astrazeneca initiated a phase i study evaluating rg-125 in humans in december 2015 , earning regulus a $ 10.0 million milestone from the collaboration . story_separator_special_tag in august 2014 , we and biogen entered into a new collaboration and license agreement to collaborate on micro rna biomarkers for ms. revenue recognized from our agreement with biogen increased to $ 1.8 million for the year ended december 31 , 2015 compared to $ 1.1 million for the year ended december 31 , 2014 . this increase was primarily a result of amortization of the $ 2.0 million upfront payment received in august 2014 which was recognized over the estimated period of performance , ending in september 2015. in january 2015 , may 2015 and september 2015 , we earned research milestone payments under the august 2014 collaboration and license agreement of $ 0.1 million , $ 0.3 million , and $ 0.3 million , respectively . revenue recognized from our product development and commercialization agreement with gsk decreased to zero for the year ended december 31 , 2015 compared to $ 3.5 million for the year ended december 31 , 2014 . in october 2014 , we received written notice from gsk of its election to terminate the product development and commercialization agreement . the effective date of the termination was january 15 , 2015. as of december 31 , 2015 , we had $ 3.3 million of deferred revenue , which consisted of payments received through our strategic alliances that have not yet been recognized in accordance with our revenue recognition policies . research and development expenses research and development expenses were $ 56.4 million for the year ended december 31 , 2015 , compared to $ 41.0 million for the year ended december 31 , 2014 . this change was primarily driven by a net increase in our aggregate pre-clinical studies and clinical trial program costs of $ 8.3 million for the year ended december 31 , 2015 , compared to the year ended december 31 , 2014 . specifically , clinical trial costs for rg-101 increased by $ 6.4 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . this increase was due to costs incurred associated with the phase ii study for rg-101 . pre-clinical study costs for rg-125 increased by $ 4.3 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . this increase was due to costs incurred associated with additional research and development activities and product manufacturing to support the initiation of a phase i clinical study . this increase was partially offset by a decrease in clinical trial costs for rg-012 of $ 2.4 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . 54 research and development personnel costs , including stock based compensation , increased by $ 5.1 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . this was principally driven by an increase in non-cash stock-based compensation expense of $ 4.1 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . in june 2015 , we incurred a non-recurring severance charge of $ 1.3 million associated with the resignation of our former chief scientific officer , including $ 0.9 million of non-cash stock-based compensation expense . we expect our research and development expenses to increase for the foreseeable future as we continue to conduct our ongoing clinical studies , initiate additional clinical studies and advance our pre-clinical research programs toward the clinic , including other ind-enabling activities . general and administrative expenses general and administrative expenses were $ 19.1 million for the year ended december 31 , 2015 compared to $ 11.5 million for the year ended december 31 , 2014 . this change was primarily driven by an increase in personnel costs , including non-cash stock based compensation , of $ 5.6 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . in june 2015 , we incurred a non-recurring severance charge of $ 3.3 million associated with the resignation of our former chief executive officer , including $ 2.3 million of non-cash stock-based compensation expense . in december 2015 , we incurred a non-recurring severance charge of $ 1.0 million associated with the resignation of our former chief business officer , including $ 0.7 million of non-cash stock-based compensation expense . in addition , changes in general and administrative expenses were due to increases in external service costs and other operating expenses associated with general business activities of $ 2.0 million for the year ended december 31 , 2015 compared to the year ended december 31 , 2014 . gain/loss from valuation of convertible note payable we recorded a loss from changes in value of the convertible note payable of $ 1.8 million for the year ended december 31 , 2015 compared to a loss of $ 12.1 million for the year ended december 31 , 2014 . changes in value were driven by changes in our stock price during the respective periods . in january 2015 , the convertible note payable was converted into 1,356,738 shares of our common stock at a conversion price of $ 4.00 per share . comparison of the years ended december 31 , 2014 and 2013 the following table summarizes the results of our operations for the periods indicated ( in thousands ) : replace_table_token_5_th revenue under strategic alliances and collaborations the following table summarizes our total revenues for the periods indicated ( in thousands ) : replace_table_token_6_th 55 revenue under strategic alliances and collaborations was $ 7.7 million for the year ended december 31 , 2014 compared to $ 19.6 million for the year ended december 31 , 2013. revenue recognized from our strategic alliance with sanofi decreased to $ 1.0 million for the year ended december 31 , 2014 , compared to $ 15.3 million in 2013. revenue recognized under the

